News at XI: moving beyond factor Xa inhibitors

JC Fredenburgh, JI Weitz - Journal of Thrombosis and Haemostasis, 2023 - Elsevier
Oral anticoagulants are a mainstay for the prevention and treatment of arterial and venous
thrombosis. Direct oral anticoagulants (DOACs) have replaced vitamin K antagonists (VKAs) …
被引用次数：20 相关文章

News at XI: Moving Beyond Factor Xa Inhibitors.

JC Fredenburgh, JI Weitz - Journal of Thrombosis and Haemostasis …, 2023 - europepmc.org
Oral anticoagulants are a mainstay for the prevention and treatment of arterial and venous
thrombosis. Direct oral anticoagulants (DOACs) have replaced vitamin K antagonists (VKAs) …

News at XI: moving beyond factor Xa inhibitors

JC Fredenburgh, JI Weitz - Journal of Thrombosis and Haemostasis, 2023 - jthjournal.org
Oral anticoagulants are a mainstay for the prevention and treatment of arterial and venous
thrombosis. Direct oral anticoagulants (DOACs) have replaced vitamin K antagonists for …

News at XI: Moving Beyond Factor Xa Inhibitors

JC Fredenburgh, JI Weitz - Journal of thrombosis and … - pubmed.ncbi.nlm.nih.gov
Oral anticoagulants are a mainstay for the prevention and treatment of arterial and venous
thrombosis. Direct oral anticoagulants (DOACs) have replaced vitamin K antagonists (VKAs) …